Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant mycobacterium tuberculosis (MDR-TB) - a novel, patentable approach to limit the emergence of XDR-TB

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 110-117

  Martins, Marta ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Ca2+ and K+ flux inhibitors; Combined therapy; Ex vivo activity; MDR TB; Mechanism of action; Mycobacterium tuberculosis; Thioridazine; XDR TB

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; THIORIDAZINE;

ARTICLE; BACTERIAL SURVIVAL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL FUNCTION; DRUG MECHANISM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INTRACELLULAR KILLING; MACROPHAGE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATENT; PHAGOSOME; POTASSIUM TRANSPORT; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CALCIUM SIGNALING; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; IMMUNOLOGIC FACTORS; ION TRANSPORT; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; PATENTS AS TOPIC; POTASSIUM; THIORIDAZINE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79959988742     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064524     Document Type: Article

References (95)

1. Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 177: 1302-1306.
2. Gernaey AM, Minnikin DE, Copley MS, Dixon RA, Middleton JC, Roberts CA. Mycolic acids and ancient DNA confirm an osteological diagnosis of tuberculosis. Tuberculosis (Edinb) 2001; 81: 259-265.
3. Morell V. Mummy settles TB antiquity debate. Science 1994; 263: 1686-1687.
4. Zink AR, Grabner W, Reischl U, Wolf H, Nerlich AG. Molecular study on human tuberculosis in three geographically distinct and time delineated populations from ancient Egypt. Epidemiol Infect 2003; 130: 239-249.
5. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1: 20-30.
6. Armstrong JA, Hart PD. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med 1975; 142: 1-16.
7. Kaufman SHE, Schaible UE. 100th anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus. TRENDS in Microbiol 2005; 13: 469-475.
8. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007; 5: 39-47.
9. Russell DG. Mycobacterium tuberculosis: Here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-577.
10. Hopewell PC. A clinical view of tuberculosis. Radiol Clin North Am 1995; 33: 641-653.
11. Lillebaek T, Kok-Jensen A, Viskum K. Bacillarity at autopsy in pulmonary tuberculosis. Mycobacterium tuberculosis is often disseminated. APMIS 2002; 110: 625-629.
12. Kusner DJ. Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol 2005; 114: 239-247.
13. Mueller P, Pieters J. Modulation of macrophage antimicrobial mechanisms by pathogenic mycobacteria. Immunobiol 2006; 21: 549-556.
14. Zhang Y. The Magic Bullets and tuberculosis drug targets. Ann Rev Pharm Toxicol 2005; 45: 529-564.
15. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, et al. Clinical concentrations of Thioridazine kill intracellular Multi-Drug Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-922.
16. Nguyen L, Pieters J. The Trojan horse: Survival tactics of pathogenic mycobacteria in macrophages. Trends in Cell Biol 2005; 15: 269-276.
17. Deretic V, Singh S, Master S, Harris J, Roberts E, Kyei G, et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol 2006; 8: 719-727.
18. DesJardin LE, Kaufman TM, Potts B, Kutzbach B, Yi H, Schlesinger LS. Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, Fc-[1]RII and the mannose receptor. Microbiol 2002; 148: 3161-3171.
19. Fenton MJ. Macrophages and tuberculosis. Curr Opin Hematol 1998; 5: 72-78.
20. Gomes MS, Paul S, Moreira AL, Appelberg R, Rabinovitch M, Kaplan G. Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. Infect Immun 1999; 67: 3199-3206.
21. Schlesinger LS. Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Curr Top Microbiol Immunol 1996; 215: 71-96.
22. Vergne I, Chua J, Singh SB, Deretic V. Cell biology of Mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol 2004; 20: 367-394.
23. Kang PB, Azad AK, Torrelles JB, Kaufmann TM, Beharka A, Tibesar E, et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005; 202: 987-989.
24. Shimada K, Takimoto H, Yano I, Kumazawa Y. Involvement of mannose receptor in glycopeptidolipid-mediated inhibition ofphagosome-lysosome fusion. Microbiol Immunol 2006; 50: 243-251.
25. Ernst JD. Macrophage Receptors for Mycobacterium tuberculosis. Infect Immun 1998; 66: 1277-1281.
26. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptormediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994; 152: 743-753.
27. Schlesinger LS. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol 1993; 150: 2920-2930.
28. Stokes RW, Haidl ID, Jefferies WA, Speert DP. Mycobacteriamacrophage interactions. Macrophage phenotype determines the nonopsonic binding of Mycobacterium tuberculosis to murine macrophages. J Immunol 1993; 151: 7067-7076.
29. Zimmerli S, Edwards S, Ernst JD. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am J Respir Cell Mol Biol 1996; 15: 760-770.
30. Flynn JL, Chany J. Immune evasion by Mycobacterium tuberculosis: Living with the enemy. Curr Opin Immunol 2003; 15: 450-5.
31. Griffiths G. On phagosome individuality and membrane signaling networks. Trends Cell Biol 2004; 14: 343-51.
32. +-ATPases. J Biol Chem 1997; 272: 29810-29820.
33. Yates RM, Hermetter A, Russell DG. The kinetics of phagosome maturation as a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. Traffic 2005; 6: 413-420.
34. Vieira OV, Botelho RJ, Grinstein S. Phagosome maturation: Aging gracefully. Biochem J 2002; 366: 689-704.
35. Anes E, Peyron P, Staali L, Jordao L, Gutierrez MG, Kress H, et al. Dynamic life and death interactions between Mycobacterium smegmatis and J774 macrophages. Cell Microbiol 2006; 8: 939-960.
36. Jordao L, Bleck CK, Mayorga L, Griffiths G, Anes E. On the killing of mycobacteria by macrophages. Cell Microbiol 2008; 10: 529-548.
37. Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J 2002; 363: 417-429.
38. Hestvik AL, Hmama Z, Av-Gay Y. Mycobacterial manipulation of the host cell. FEMS Microbiol Rev 2005; 29: 1041-1050.
39. +)-ATPases--nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002; 3: 94-103.
40. Anes E, Kühnel MP, Bos E, Moniz-Pereira J, Habermann A, Griffiths G. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat Cell Biol 2003; 5: 793-802.
41. Chua J, Vergne I, Master S, Deretic V. A tale of two lipids: Mycobacterium tuberculosis phagosome maturation arrest. Curr Opin Microbiol 2004; 7: 71-77.
42. De Chastellier C, Thillo L. Cholesterol depletion in Mycobacterium avium-infected macrophages overcomes the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome-derived autophagic vacuoles. Cell Microbiol 2006; 8: 242-256.
43. Kuehnel MP, Goethe R, Habermann A, Mueller E, Rohde M, Griffiths G, et al. Characterization of the intracellular survival of Mycobacterium avium sp. paratuberculosis: Phagosomal pH and fusogenicity in J774 macrophages compared with other mycobacteria. Cell Microbiol 2001; 3: 551-566.
44. Warner DF, Mizrahi V. The survival kit of Mycobacterium tuberculosis. Nature Med 2007; 13: 282-284.
45. Stober CB, Lammas DA, Li CM, Kumararatne DS, Lightman SL, McArdle CA. ATP-mediated killing of Mycobacterium bovis bacilli Calmette-Guérin within human macrophages is calcium dependent and associated with the acidification of mycobacteriacontaining phagosomes. J Immunol 2001; 166: 6277-6286.
46. Thompson CR, Iyer SS, Melrose N, VanOosten R, Johnson K, Pitson SM, et al. Sphingosine kinase 1 (SK1) is recruited to nascent phagosomes in human macrophages: Inhibition of SK1 translocation by Mycobacterium tuberculosis. J Immunol 2005; 174: 3551-3561.
47. Koul S, Somayajulu A, Advani MJ, Reddy H. A novel calcium binding protein in Mycobacterium tuberculosis-potential target for trifluoperazine. Indian J Exp Biol 2009; 47: 480-488.
48. Chitturi S, George J. Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002, 22: 169-183.
49. Moore DE. Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Saf 2002, 25: 345-372.
50. Amaral L, Viveiros M, Molnar J. Antimicrobial activity of phenothiazines. In vivo 2004; 18: 725-732.
51. Amaral L, Martins M, Viveiros M. Phenothiazines as anti-multidrug resistant tubercular agents. Infect Disord Drug Targets 2007; 7: 257-265.
52. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004, 45: 371-7.
53. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158: 1774-82.
54. Martins A, Machado L, Costa S, Cerca P, Spengler G, Viveiros M, et al. Role of calcium in the efflux system of Escherichia coli. Int J Antimicrob Agents 2011, In Press.
55. Motohashi N. Phenothiazines and calmodulin (review). Anticancer Res 1991; 11: 1125-64.
56. Roufogalis BD, Minocherhomjee AM, Al-Jobore A. Pharmacological antagonism of calmodulin. Can J Biochem Cell Biol 1983; 61: 927-33.
57. + channel is essential for innate immunity. Nature 2004; 427: 853-8.
58. + flux. Nature 2002; 416: 291-7.
59. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multi-drug resistant Mycobacterium tuberculosis by compounds that affect the activity of MDR efflux pumps: A review. J Antimicrob Chemother 2007; 59: 1237-46.
60. Ordway D, Viveiros M, Leandro C, Jorge-Arroz M, Molnar J, Kristiansen JE, et al. Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J Infect Chemother 2002; 8: 227-31.
61. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-8.
62. Martins M, Schelz Z, Martins A, Molnar J, Hajös G, Riedl Z, et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 2007; 29: 338-40.
63. Kaminska M. Role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Med Cracov 1967; 9: 115-43.
64. Daniel WA, Wojcikowski J. Interactions between promazine and antidepressants at the level of cellular distribution. Pharmacol Toxicol 1997; 81: 259-64.
65. Daniel WA, Wojcikowski J. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur Neuropsychopharmacol 1999; 9: 483-91.
66. Daniel WA, Wojcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol Appl Pharmacol 1999; 158: 115-24.
67. Daniel WA, Wojcikowski J, Palucha A. Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br J Pharmacol 2001; 134: 807-14.
68. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemother 1992; 38: 410-9.
69. Martins M, Viveiros M, Ramos J, Couto I, Molnar J, Boeree M, et al. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int J Antimicrob Agents 2009; 33: 479-82.
70. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In vivo 2007; 21: 771-5.
71. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5: e12640.
72. Chakrabarty AN, Bhattacharya CP, Dastidar SG. Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. APMIS 1993; 101: 449-54.
73. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35: 524-6.
74. Abbate E, Vescoso M, Natiello M, Cufre M, Garcia A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Revista Argentina de Medicina Respiratoria 2007; 1: 19-25.
75. Di Perri G, Bonora S. Which agents should we use for the treatment of multi-drug resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004; 54: 593-602.
76. Gadre DV, Talwar V, Gupta HC, Murthy PS. Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis. Int Clin Psychopharmacol 1998; 13: 129-31.
77. Ratnakar P, Murthy PS. Trifluoperazine inhibits the incorporation of labelled precursors into lipids, proteins and DNA of Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 1993; 110: 291-4.
78. Ratnakar P, Rao SP, Sriramarao P, Murthy PS. Structureantitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int Clin Psychopharmacol 1995; 10: 39-43.
79. Salih FA, Kaushik NK, Sharma P, Choudary GV, Murthy PS, Venkitasubramanian TA. Calmodulin-like activity in mycobacteria. Indian J Biochem Biophys 1991; 28: 491-5.
80. Teh JS, Yano T, Rubin H. Type II NADH: Menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect Disord Drug Targets 2007; 7: 169-81.
81. Csiszar K, Molnar J. Mechanism of action of tricyclic drugs on Escherichia coli and Yersinia enterocolitica plasmid maintenance and replication. Anticancer Res 1992; 12: 2267-72.
82. Molnár J, Földeák S, Nakamura MJ, Gaizer F, Gutmann F. The influence of charge transfer complex formation on the antibacterial activity of some tricyclic drugs. Xenobiotica 1991; 21: 309-16.
83. Tb Alliance. Global Alliance for TB Drug Development. Our Portfolio. Available at: http://www.tballiance.org/home/home.php (Accessed on: February 4, 2011).
84. Glaxo Group Ltd. Use of pyrrolonaphthyridine derivatives for manufacture of medicament for treatment of tuberculosis. EP2005995 (2008).
85. Glaxo Group Ltd. Novel bicyclic nitrogen-containing compound for treatment of bacterial infection in mammals, its salt, solvate or N-oxide. EP1992628 (2008).
86. Hegyi, J.F., Aelterman, W.A.A., Lang, Y.L., Stokbroekx, S.C.M., Leys, C., Van Remoortere, P.J.M., Faure, A. New fumarate salt of (alpha S, beta R)-6-bromo-alpha-(2-(dimethylamino)ethyl)-2- methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol, preferably (2E)-2-butenedioate, useful to treat or prevent mycobacterial infection. US20100028428 (2010).
87. Hernandez, P.R., Lopez, C.F.L. Treatment kit which assists with antibiotic therapy for intracellular infectious diseases. US20060251657 (2006).
88. Glazner, G.W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators. US20020107193 (2002).
89. Gordon, P. Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals. US5157024 (1992).
90. Gupta S, Salam N, Srivastava V, Singla R, Behera D, Khayyam KU, et al. Voltage Gated Calcium Channels Negatively Regulate Protective Immunity to Mycobacterium tuberculosis. PLoS ONE 2009; 4: e5305.
91. Gupta, S., Singla, R., Behera, D., Khayyam, K.U., Korde, R., Malhotra, P., Natarajan, K., Srivastava, V. Pharmaceutical compositions containing calcium channel blockers for treatment of Tuberculosis. WO2010026602 (2010).
92. He, X., Zhuang, Y., Zhang, X., Wang, H. Novel Mycobacterium tuberculosis fusion protein having immunizing activity of Mycobacterium tuberculosis antigen, useful for preparing drugs for preventing or treating tuberculosis. EP1978036A1 (2008).
93. Andersen, P., Weldingh, K., Hansen, C.V., Florio, W., Okkels, L.M.M., Skjoet, R.L.V., Rosenkrands, I. Novel polypeptide of somatic protein extract useful as vaccine against virulent Mycobacterium infection, isolated from cell wall, cell membrane and cytosol. EP1787994 (2007).
94. James, B.W., Bacon, J., Marsh, P. New mycobacterial peptide, its fragment, variant or derivative, useful as vaccine for treating or preventing mycobacterial infections, and as diagnostic reagents for identifying such infections. US7393539 (2008).
95. Delphion Research intellectual property network. Available at http://www.delphion.com/. (Accessed on: March 28, 2011).